# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Keybanc analyst Scott Schoenhaus initiates coverage on LifeMD (NASDAQ:LFMD) with a Overweight rating and announces Price Tar...
- SEC Filing
B. Riley Securities analyst William Woods reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $12 price target.